Home
Dr. Ronald H.W. Lorijn
“Passionately working with a first class team of experts on improving the lives of those who today have no prospects for a real cure for their serious disease makes one's own life worth living.”
Dr. Ronald H.W. Lorijn
Chief Executive Officer
 More real stories from the AMT team.
Latest news
November 2008
Dr. Ronald Lorijn Opened Trading Day NYSE Euronext Amsterdam
read more
October 2008
AMT intends to incorporate additional data to its Marketing Authorization Dossier for Glybera®
read more
September 2008
AMT Obtains License to Amgen's GDNF Gene to Develop Treatment for Parkinson's Disease with AMT's Proprietary Gene Therapy Platform
read more
September 2008
Roushan Khandaker Group Initiates Coverage of AMT. Price Target of EUR 16.86 over an 18 to 36 Month Period
read more
August 2008
Amsterdam Molecular Therapeutics Reports Half Year Results 2008
read more
August 2008
AMT to Release Half Year 2008 Results on August 13, 2008
read more
July 2008
AMT Appoints Director Global Marketing and Sales
read more
July 2008
AMT Starts Collaboration With St. Jude Children's Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy
read more
June 2008
AMT prepares for submission of Marketing Authorization Dossier for AMT-011 (Glybera®)
read more
June 2008
AMT makes important advance in the development of its gene therapy for Hemophilia B - Company Accesses Technology to Prevent Immune Response
read more
Last updated: November 19, 2008